Farmacovigilanza degli inibitori selettivi della cicloossigenasi-2: Le popolazioni a rischio

Translated title of the contribution: Post-marketing surveillance of cyclooxygenase-2 selective inhibitors: Population at risk

Caterina Anecchino, Simona Monte, Rita Salotti, Domenica Costantino, Elisa Sasso, Antonella Di Matteo, Marilena Romero

Research output: Contribution to journalArticlepeer-review

Abstract

This is the second article about the study. This work focused on a cohort of patients defined «at risk» because of age, different comorbidities and co-therapies. 1296 patients at risk (66.3% of general sample) were identified. The most frequent risk factor was old age (over 70 years) followed by hypertension and gastrointestinal comorbidities. Patients' clinical condition at follow-up was analysed in order to identify eventually adverse reactions after Coxib assumption. The aim of the study was to promote an active collaboration with general practitioners in order to underline the importance of their role in Pharmacovigilance specifically regarding to new drugs.

Translated title of the contributionPost-marketing surveillance of cyclooxygenase-2 selective inhibitors: Population at risk
Original languageItalian
Pages (from-to)16-20
Number of pages5
JournalGiornale Italiano di Farmacia Clinica
Volume17
Issue number1
Publication statusPublished - Jan 2003

ASJC Scopus subject areas

  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Post-marketing surveillance of cyclooxygenase-2 selective inhibitors: Population at risk'. Together they form a unique fingerprint.

Cite this